Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Signal transducer and activator of transcription 4 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Signal transducer and activator of transcription 4 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Signal transducer and activator of transcription 4, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Signal transducer and activator of transcription 4. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Signal transducer and activator of transcription 4. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Signal transducer and activator of transcription 4 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Signal transducer and activator of transcription 4
partner:
Reaxense
upacc:
Q14765
UPID:
STAT4_HUMAN
Alternative names:
-
Alternative UPACC:
Q14765; Q96NZ6
Background:
Signal transducer and activator of transcription 4 (STAT4) is a pivotal transcriptional regulator predominantly expressed in hematopoietic cells. It orchestrates cellular growth, differentiation, and immune responses. STAT4 is instrumental in T-helper 1 cell differentiation and interferon-gamma production, contributing to immune system precision. Its activation involves tyrosine phosphorylation upon IL12 or IFN-gamma stimulation, leading to nuclear translocation and gene transcription initiation.
Therapeutic significance:
STAT4's involvement in systemic lupus erythematosus and rheumatoid arthritis underscores its therapeutic potential. Given its critical role in immune response modulation and disease pathogenesis, targeting STAT4 could offer novel treatment avenues for these autoimmune conditions. Understanding STAT4's mechanisms opens doors to innovative therapeutic strategies, potentially transforming patient outcomes in autoimmune diseases.